TX 1920

Drug Profile

TX 1920

Latest Information Update: 26 Apr 2002

Price : $50

At a glance

  • Originator Nonindustrial sources
  • Class Antineoplastics; Radiosensitisers
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 13 Apr 2000 New profile
  • 13 Apr 2000 Preclinical development for Solid tumours in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top